This book helps investigators understand the basic concepts and practical concerns associated with the use of antisense oligonucleotides to modify gene expression. It provides a balanced overview of the field from a very practical standpoint and describes this cutting-edge technology that has been embraced because of its potential therapeutic uses in clinical conditions ranging from cancers to infectious diseases. Applied Antisense Oligonucleotide Technology provides the basic concepts as well as the practical concerns associated with the use of antisense oligonucleotides to modify gene…mehr
This book helps investigators understand the basic concepts and practical concerns associated with the use of antisense oligonucleotides to modify gene expression. It provides a balanced overview of the field from a very practical standpoint and describes this cutting-edge technology that has been embraced because of its potential therapeutic uses in clinical conditions ranging from cancers to infectious diseases.
Applied Antisense Oligonucleotide Technology provides the basic concepts as well as the practical concerns associated with the use of antisense oligonucleotides to modify gene expression. Chapters include oligonucleotide chemistry, DNA triplex formation, delivery mechanisms, pharmocokinetics, toxicity, oligonucleotides.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Cy A. Stein is the editor of Applied Antisense Oligonucleotide Technology, published by Wiley. Arthur M. Krieg is the editor of Applied Antisense Oligonucleotide Technology, published by Wiley.
Inhaltsangabe
CHEMISTRY, OLD AND NEW. Oligonucleoside Methylphosphonates: Synthesis and Properties (P. Miller). Oligo(Nucleoside Phosphorothioate)s (P. Guga, et al.). Modified Oligodeoxynucleotides as Antisense Therapeutics (P. Seeberger & M. Caruthers). Novel Chemistry (K. Altmann, et al.). OLIGONUCLEOTIDE INTERNALIZATION, MECHANISM OF ACTION, AND NON-SEQUENCE SPECIFICITY. Cellular Uptake and Biodistribution of Oligodeoxynucleotides (B. Hanss, et al.). Use of Cationic Lipid Complexes for Antisense Oligonucleotide Delivery (C. Bennett). Nonantisense Effects of Antisense Oligonucleotides (L. Neckers & K. Iyer). Ribonuclease H-Mediated Antisense Effects of Oligonucleotides and Controls for Antisense Experiments (D. Tidd). SEQUENCE-SPECIFIC INHIBITION OF GENE EXPRESSION. The Development of C-5 Propyne Oligonucleotides as Inhibitors of Gene Function (W. Flanagan & R. Wagner). The Use of Antisense Oligonucleotides to Inhibit Expression of Isozymes of Protein Kinase C (N. Dean, et al.). BCR-ABL as a Target for Antisense Intervention (S. O'Brien & T. Smetsers). The NF-kB Transcription Factor (R. Narayanan). Disruption of the Map Kinase Signaling Pathway Using Antisense Oligonucleotide Inhibitors Targeted to RAS and RAF Kinase (B. Monia). Protein Kinase A-Directed Antisense Blockade of Cancer Growth: Single Gene-Based Therapeutic Approach (Y. Cho-Chung). Use of Antisense Oligonucleotides in the Central Nervous System: Why Such Success? (M. McCarthy). APPLIED ANTISENSE OLIGONUCLEOTIDE THERAPEUTICS. Perturbing Hematopoietic Cell Gene Expression with Oligodeoxynucleotides: Research and Clinical Applications (A. Gewirtz & M. Ratajczak). BCL2 (B. Jansen & B. Brown). Biological Activity of Guanosine Quartet-Forming Oligonucleotides (R. Rando & M. Hogan). OLIGONUCLEOTIDES AS ANTI-HIV AGENTS. Perspectives on Antisense Technology Against HIV (J. Gee, et al.). In Vivo Pharmacokinetics of Oligonucleotides (S. Agrawal). Early Clinical Trails with Gem 91, A Systemic Oligodeoxynucleotide (R. Martin). THERAPEUTIC OLIGONUCLEOTIDE DATA BASE: PHARMACOKINETICS, IMMUNE STIMULATION, AND USE AS ANTIRESTENOTIC AGENTS. Antisense Therapy to Inhibit Angioplasty Restenosis (L. Rabbani & W. Wang). Pharmacokinetics of Oligonucleotides: A Review of Current Knowledge and Issues for the Future (T. Wallace & P. Cossum). Leukocyte Stimulation by Oligodeoxynucleotides (A. Krieg). SELECTED OLIGODEOXYNUCLEOTIDE DEVELOPMENTAL TOPICS: SPLICING AND TRIPLEXES. Modification of Alternative Splicing of Pre-mRNA by Antisense Oligonucleotides (R. Kole). Gene-Targeted Triple-Helix-Forming Oligonucleotides (F. Svinarchuk & C. Malvy). Triplex-Forming Oligonucleotides for Genetic Manipulation: An Alternative View (A. Faruqi & P. Glazer). A REVIEW OF RIBOZYME TECHNOLOGY. Therapeutic Ribozymes: Principles, Applications, and Problems (J. Rossi). Index.
CHEMISTRY, OLD AND NEW. Oligonucleoside Methylphosphonates: Synthesis and Properties (P. Miller). Oligo(Nucleoside Phosphorothioate)s (P. Guga, et al.). Modified Oligodeoxynucleotides as Antisense Therapeutics (P. Seeberger & M. Caruthers). Novel Chemistry (K. Altmann, et al.). OLIGONUCLEOTIDE INTERNALIZATION, MECHANISM OF ACTION, AND NON-SEQUENCE SPECIFICITY. Cellular Uptake and Biodistribution of Oligodeoxynucleotides (B. Hanss, et al.). Use of Cationic Lipid Complexes for Antisense Oligonucleotide Delivery (C. Bennett). Nonantisense Effects of Antisense Oligonucleotides (L. Neckers & K. Iyer). Ribonuclease H-Mediated Antisense Effects of Oligonucleotides and Controls for Antisense Experiments (D. Tidd). SEQUENCE-SPECIFIC INHIBITION OF GENE EXPRESSION. The Development of C-5 Propyne Oligonucleotides as Inhibitors of Gene Function (W. Flanagan & R. Wagner). The Use of Antisense Oligonucleotides to Inhibit Expression of Isozymes of Protein Kinase C (N. Dean, et al.). BCR-ABL as a Target for Antisense Intervention (S. O'Brien & T. Smetsers). The NF-kB Transcription Factor (R. Narayanan). Disruption of the Map Kinase Signaling Pathway Using Antisense Oligonucleotide Inhibitors Targeted to RAS and RAF Kinase (B. Monia). Protein Kinase A-Directed Antisense Blockade of Cancer Growth: Single Gene-Based Therapeutic Approach (Y. Cho-Chung). Use of Antisense Oligonucleotides in the Central Nervous System: Why Such Success? (M. McCarthy). APPLIED ANTISENSE OLIGONUCLEOTIDE THERAPEUTICS. Perturbing Hematopoietic Cell Gene Expression with Oligodeoxynucleotides: Research and Clinical Applications (A. Gewirtz & M. Ratajczak). BCL2 (B. Jansen & B. Brown). Biological Activity of Guanosine Quartet-Forming Oligonucleotides (R. Rando & M. Hogan). OLIGONUCLEOTIDES AS ANTI-HIV AGENTS. Perspectives on Antisense Technology Against HIV (J. Gee, et al.). In Vivo Pharmacokinetics of Oligonucleotides (S. Agrawal). Early Clinical Trails with Gem 91, A Systemic Oligodeoxynucleotide (R. Martin). THERAPEUTIC OLIGONUCLEOTIDE DATA BASE: PHARMACOKINETICS, IMMUNE STIMULATION, AND USE AS ANTIRESTENOTIC AGENTS. Antisense Therapy to Inhibit Angioplasty Restenosis (L. Rabbani & W. Wang). Pharmacokinetics of Oligonucleotides: A Review of Current Knowledge and Issues for the Future (T. Wallace & P. Cossum). Leukocyte Stimulation by Oligodeoxynucleotides (A. Krieg). SELECTED OLIGODEOXYNUCLEOTIDE DEVELOPMENTAL TOPICS: SPLICING AND TRIPLEXES. Modification of Alternative Splicing of Pre-mRNA by Antisense Oligonucleotides (R. Kole). Gene-Targeted Triple-Helix-Forming Oligonucleotides (F. Svinarchuk & C. Malvy). Triplex-Forming Oligonucleotides for Genetic Manipulation: An Alternative View (A. Faruqi & P. Glazer). A REVIEW OF RIBOZYME TECHNOLOGY. Therapeutic Ribozymes: Principles, Applications, and Problems (J. Rossi). Index.
Rezensionen
"This book will be most useful to workers in the field and advanced graduate students." --The Quarterly Review of Biology, June 1999
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
